KYTXKyverna Therapeutics, Inc.

Nasdaq kyvernatx.com


$ 7.37 $ 0.04 (0.54 %)    

Monday, 09-Sep-2024 15:59:57 EDT
QQQ $ 455.25 $ 5.77 (1.29 %)
DIA $ 409.08 $ 4.58 (1.13 %)
SPY $ 546.60 $ 6.05 (1.12 %)
TLT $ 99.96 $ 0.43 (0.43 %)
GLD $ 231.58 $ 0.97 (0.42 %)
$ 7.38
$ 7.35 x 200
$ 7.38 x 100
-- - --
$ 6.30 - $ 35.06
193,501
na
318.42M
$ -0.79
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-12-2024 06-30-2024 10-Q
2 05-14-2024 03-31-2024 10-Q
3 03-26-2024 12-31-2023 10-K
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

Core News & Articles

HC Wainwright & Co. analyst Mitchell Kapoor maintains Kyverna Therapeutics (NASDAQ:KYTX) with a Neutral and lowers the p...

Core News & Articles

Kyverna Therapeutics (NASDAQ:KYTX) reported quarterly losses of $(0.67) per share which missed the analyst consensus estimate o...

Core News & Articles

JP Morgan analyst Brian Cheng maintains Kyverna Therapeutics (NASDAQ:KYTX) with a Overweight and lowers the price target fro...

 cell-therapy-mostly-used-for-blood-cancer-shows-efficacy-in-autoimmune-diseases-as-well-but-there-are-challenges

CAR-T therapy, originally used for blood cancers, shows promising results in treating lupus, as evidenced by Janina Paech's...

Core News & Articles

HC Wainwright & Co. analyst Mitchell Kapoor reiterates Kyverna Therapeutics (NASDAQ:KYTX) with a Neutral and maintains $...

Core News & Articles

The application was evaluated based on the positive clinical outcomes of KYV-101 in patients treated in Germany under a named-p...

Core News & Articles

HC Wainwright & Co. analyst Mitchell Kapoor initiates coverage on Kyverna Therapeutics (NASDAQ:KYTX) with a Neutral rati...

Core News & Articles

This IND clearance expands the use of KYV-101 CAR T-cell therapy in a Phase 2, open-label KYSA-8 clinical trial targeting a dev...

Core News & Articles

Patient received KYV-101, a fully human anti-CD19 CAR T-cell product candidate, as part of a named-patient treatment option aft...

 why-kyverna-therapeutics-stock-is-sinking

Kyverna Therapeutics shares are falling Friday. The company released a presentation on KYV-101, its CD19 CAR T-cell candidate. ...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION